1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
North America Biopsy Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Technology, Application, and Country

North America Biopsy Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Technology, Application, and Country

  • July 2020
  • 159 pages
  • ID: 5934826
  • Format: PDF
  • The Insight Partners
Up to $1000 off Until May 10th 2021


Table of Contents

Search Inside

The North America biopsy devices market is expected to reach US$ 1,466.30 million by 2027 from US$ 897.60 million in 2019; it is estimated to grow at a CAGR of 6.5% during 2020-2027.The biopsy devices marketis growing primarily due to the increasing cancer prevalence, and government support and initiativesin the region. Factors such limitations associated to biopsy devices damage the growth of the market. Additionally, increasing awareness regarding early disease detectionand consistent improvements in product designs are the factors that are likely to fuel the growth of the biopsy devices market during the forecast period.
Biopsy is a medical examination implemented by surgeons, interventional radiologists, or interventional cardiologists to extract sample cells or tissues for the identification and detection of diseases.The tissue is generally observed under a microscope by pathologists; it can also be examined via chemical methods.

Biopsies are most commonly performed to identify cancerous and inflammatory conditions.
Governments in North American countriesare supportive toward promoting the early detection of cancer and undertake various initiatives for the same.For instance, the National Institutes of Health (NIH) started a new initiative called Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment.

The purpose of this initiative is to establish a Public-Private Partnership Program for the development of new technologies or validate the existing technologies, methods, and assays for the capture and quantification of tumor-associated cells, RNA, DNA, or exosomes in the body fluids of patients with an early-stage disease or those who are at high risk. The initiative emphasizes detecting cancer in early stages, distinguishing between aggressive from nonaggressive cancers, and differentiating benign disease from cancer.
The NCI’s commitment toward funding the R&D of advanced clinical technology also encourages investigators to expand their research scope to include the early detection and accelerate clinical adoption of these promising technologies. For instance, in 2017,the estimated national expenditures for cancer care in the US were US$ 147.3 billion. In the coming years, these costs are likely to increase with the aging population and increasing cancer prevalence. The expenditure is also likely to shoot up as new, and often more expensive, treatments are adopted as standards of care, which is a major factor boosting the growth of the biopsy devices in the North America market.
In the US, due to an increasing number ofCOVID-19 infected patients, healthcare professionals and leading organizations are rechanneling the flow of healthcare resources from R&D to primary care, which is slowing down the process of innovation.Further, the COVID-19 pandemic spread is also hindering the conduct of clinical trials and drug development, and the operations of diagnostic industry in the US.

For instance, California-based Lucence Diagnostics Pte Ltd., a known player in the biopsy products industry, has diverted operations to manufacture COVID-19 diagnostics kits.
Moreover, according to a recent survey by Medscape in April 2020, substantial disruption in routine cancer carehas been witnessed,including tests for screening and diagnosis in suspected cases, to their treatment as a result of the COVID-19 pandemic. The rapid increase in the number of COVID-19 patients in the US and Canada is likely to hamper the growth of biopsy devices market and result in the slowdown of the market growth in the near future.
In 2019, the needle-based biopsy segment accounted for the largest share of the North America biopsy devices market.The growth of the market for this segment attributes to rising adoption of needle based-biopsy due to its high accuracy, with minimal injury associated with the procedure.

Further, the segment is also likely to register the highest CAGR in the market during the forecast period.
A few of the significant secondary sources associated with the North America Biopsy Devices market report are the World Health Organization (WHO), Centers of Disease Control and Prevention (CDC), American Cancer Society, and Canadian Cancer Society.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on